Agenda

Date and Time	Title
Jun 23, 2022 1:55pm - 2:45pm (Pacific)	Keynote Address: Welcome & Introductions 1:55PM PT \| Welcome and Introductions Won Seog Kim, MD, PhD 2:00PM PT \| Introduction of Keynote Speaker Pier Luigi Zinzani, MD 2:06PM PT \| Keynote Address: The Gradual Evolution of Treatment in PTCL: Is it Time to Embrace a New Punctuated Equilibrium? Owen A. O'Connor, MD, PhD
Jun 23, 2022 3:05pm - 4:45pm (Pacific)	Session I: Epidemiology & Classification 3:05PM PT \| Introduction & In Memoriam: D. Thomas Waldmann and Dr. Joe Bertino Francine M. Foss, MD Owen A. O’Connor, MD, PhD 3:10PM PT \| A Focus on Rare PTCL Subtypes: Clinicopathologic Correlations Pier Paolo Piccaluga, MD, PhD 3:25PM PT \| Recommendations from the Clinical Advisory Committee of the International Consensus Classification of Myeloid and Lymphoid Neoplasms Elaine S. Jaffe, MD 3:40PM PT \| 2022 International Consensus Classification (ICC) Guidelines for Follicular Helper and Intestinal T-Cell Lymphomas Laurence de Leval, MD, PhD 3:55PM PT \| Agent Orange and the Link with CTCL and PTCL in Veterans: What Does the Data Say? Helen Ma, MD 4:10PM PT \| Methyltransferase Inhibitors Restore SATB1 Protective Activity Against Cutaneous T cell Lymphoma in Mice Carly Harro 4:25PM PT \| Panel Discussion Francine M. Foss, MD Pier Paolo Piccaluga, MD, PhD Elaine S. Jaffe, MD Laurence de Leval, MD, PhD Helen Ma, MD Carly Harro
Jun 24, 2022 8:10am - 9:47am (Pacific)	Session II: Molecular Biology & Pathogenesis 8:10AM PT \| Welcome Won Seog Kim, MD, PhD 8:15AM PT \| Molecular Classification of the PTCL: What's New and How Will it Influence Practice? Javeed Iqbal, PhD 8:45AM PT \| Most Recent Advances in the Pathogenesis of T-Cell Lymphoma Kojo S. J. Elenitoba-Johnson, MD 9:00AM PT \| How Does One Measure MRD in Patients with Hematologic Malignancies, and Why? Matthew Ahearne, MD, MRCP 9:15AM PT \| The Status of MRD Analyses in TCLF John Chan, MD 9:30AM PT \| Panel Discussion Won Seog Kim, MD, PhD Javeed Iqbal, PhD Kojo S. J. Elenitoba-Johnson, MD Matthew Ahearne, MD, MRCP John Chan, MD
Jun 24, 2022 10:00am - 11:40am (Pacific)	Session III: T-Cell Lymphoma Subtypes 10:00AM PT \| Welcome Won Seog Kim, MD, PhD 10:05AM PT \| Liquid Biopsy in PTCLs: Potential Clinical Applications and Limitation Won Seog Kim, MD, PhD 10:20AM PT \| Genetic Susceptibility to NKTCL? Jin-Xin Bei, PhD 10:35AM PT \| Prognostic Value of Single-Nucleotide Polymorphisms for Extranodal Natural Killer/T-Cell Lymphoma: The Identification of Risk Factors in the Molecular Era Quingquing Cai, MD, PhD 10:50AM PT \| How Animal Models of Adult T-Cell Leukemia Have Changed Our Thinking Around Disease Biology Ali Bazarbachi, MD, PhD 11:05AM PT \| The role of Tet2 in Select subtypes of PTCL: A focus on AITL and PTCL-TFH. Teresa M. Palomero, PhD 11:20AM PT \| Genomic Landscape of ATLL Keisuke Kataoka, MD, PhD 11:35AM PT \| Panel Discussion Won Seog Kim, MD, PhD Jin-Xin Bei, PhD Quingquing Cai, MD, PhD Ali Bazarbachi, MD, PhD Teresa M. Palomero, PhD Keisuke Kataoka, MD, PhD
Jun 24, 2022 1:35pm - 3:40pm (Pacific)	Session IV: Treatment – Chemotherapy vs Non-Chemotherapy Options in the Front-Line 1:35PM PT \| Introduction Owen A. O'Connor, MD, PhD 1:40PM PT \| CHOP-Romidepsin in the Front Line Michael Crump, MD 1:55PM PT \| Still CHOP? The Merits or NOT of CHOP Addition Studies Seok Jin Kim, MD, PhD 2:10PM PT \| What’s the Argument for Non-Chemotherapy Options in the Front Line Enrica Marchi, MD, PhD 2:25PM PT \| Live Debate: I Transplant All Eligible Patients in the Front-Line Norbert Schmitz, MD, PhD 2:40PM PT \| I Never Recommend ASCT in the Front Line Pier Luigi Zinzani, MD 2:55PM PT \| The Nowadays Role of AlloSCT in the Treatment of PTCL Paolo Corradini, MD 3:10PM PT \| Panel Discussion Owen A. O'Connor, MD, PhD Seok Jin Kim, MD, PhD Enrica Marchi, MD, PhD Norbert Schmitz, MD, PhD
Jun 24, 2022 3:50pm - 5:20pm (Pacific)	Session V: CTCL 3:50PM PT \| Introduction Owen A. O'Connor, MD, PhD 3:55PM PT \| Quantitating Clinical Benefits of New Treatments in CTCL: Is it Time to Move on from SWAT? H. Miles Prince, MD 4:10PM PT \| What Have we Learned about the Treatment of Advanced Stage MF from the ProClipi Registry? Julia Scarisbrick, MD, MBChB 4:25PM PT \| Transformed MF: Clinical Approaches and Novel Molecular Insights Francine M. Foss, MD Pei-Ling Chen, MD, PhD 4:40PM PT \| Novel Agents and Combinations in CTCL Michael Girardi, MD 4:55PM PT \| Panel Discussion Owen A. O'Connor, MD, PhD H. Miles Prince, MD Julia Scarisbrick, MD, MBChB Francine M. Foss, MD Michael Girardi, MD
Jun 24, 2022 5:25pm - 6:15pm (Pacific)	Poster Presentations
Jun 25, 2022 8:05am - 10:10am (Pacific)	Session VI: Novel Therapies on the PTCL Horizon 8:05AM PT \| Introductions Owen A. O'Connor, MD, PhD 8:10AM PT \| Adoptive Cellular Treatment of PTCL: Just How Much Longer Should This Take? Marco Ruella, MD 8:25AM PT \| Targeting T-cells with Bispecific Antibodies: Are There any Prospects for Application in PTCL? Lawrence G. Lum, MD 8:40AM PT \| The Newest Small Molecules Under Study in PTCL. Wei Z. Ai, MD, PhD 8:55AM PT \| Monoclonal Antibodies Wei Z. Ai, MD, PhD 9:10AM PT \| The Landscape of New Drugs in Extranodal NK/T-cell Lymphoma Liang Wang, MD 9:25AM PT \| Transformation of Grade I Follicular Lymphoma to Anaplastic Large Cell Lymphoma CD 30 + ALK 1 - with Complete Response to Brentuximab Vedotin and High - Dose Methotrexate Mubarak Al Mansour, MD 9:40AM PT \| Panel Discussion Owen A. O'Connor, MD, PhD Marco Ruella, MD Lawrence G. Lum, MD Wei Z. Ai, MD, PhD Liang Wang, MD Mubarak Al Mansour, MD
Jun 25, 2022 10:20am - 11:30am (Pacific)	Session VII: Industry Innovations 10:20AM PT \| Introductions Francine M. Foss, MD 10:25AM PT \| Development of allogeneic CAR-T product for T cell malignancies using RNA interference Hyung Cheol Kim, PhD 10:40AM PT \| Engineered Myeloid Cells for T Cell Lymphoma Michele Gerber, MD 10:55AM PT \| How Nanoparticle Chemistry is Changing our Approach to Therapeutics: The mRNA COVID19 Paradigm Mark Kester, PhD 11:10AM PT \| Oral CCR4 Antagonist FLX475 Antitumor Activity Against Extranodal NK/T-cell Lymphoma, Nasal Type William Ho, MD, PhD 11:25AM PT \| Targeting Cell Surface Heat Shock Protein 70 for T-cell Lymphomas Robert Z. Orlowski, MD, PhD 11:40AM PT \| PI3K in PTCL Bong-Seog Kim, MD, PhD 11:55AM PT \| Panel Discussion Francine M. Foss, MD Hyung Cheol Kim, PhD Michelle Gerber, MD Mark Kester, PhD William Ho, MD, PhD Robert Z. Orlowski, MD, PhD Bong-Seog Kim, MD, PhD
Jun 25, 2022 11:50am - 12:05pm (Pacific)	Session VIII: Wrap-Up Highlights 12:15pm PT \| TCLF 2022 Summary Roundtable Francine M. Foss, MD Owen A. O'Connor, MD, PhD John Chan Miles Prince 12:55pm PT \| Closing Remarks Francine Foss, MD Owen O'Conner, MD, PhD Won-Seog Kim, MD, PhD